For Health Partners
Your patients' metabolism doesn't stop between appointments.
Now you can see it in real time.
The first FDA-cleared continuous glucose monitoring system for weight and metabolic management. No prescription required. Built for the way functional medicine practitioners actually work. Start in seconds.
The Stats
Running the Actual Numbers
of your patients are metabolically unhealthy before they walk in the door
daily app engagement in month one — real behavior change between visits
of Signos members report measurable success in month one
The Problem
The Gap in Functional Medicine Practice
Functional medicine has always been ahead of conventional care in understanding metabolic dysfunction. Practitioners order the right panels, design the right protocols, and have the right conversations. But between appointments, patients are flying blind.
They know what you told them. They don't know what their body is actually doing in response.
Three gaps practitioners tell us they can't solve today:
Labs are snapshots. Continuous metabolic function goes unseen between visits.
For Practitioners
The Clinical Visibility You Have Always Wanted
As a Signos partner, you get access to tools that make your practice more effective:
Real-Time Population Outcomes Dashboard
Monitor adoption, engagement, and metabolic outcomes across your referred patient population. See time-in-range trends, glucose stability improvements, behavior change metrics, and engagement rates without waiting for labs. Leading indicators of long-term success are available from week one.
Engagement That Closes the Adherence Gap
Patients check the app an average of 11 times per day in month one. Active daily engagement with metabolic health, driven by the feedback loop your protocols depend on.
Precision Data That Sharpens Your Protocols
Patients bring real data: weeks of continuous glucose response to specific foods, activity patterns, sleep quality, and stress events. Adjust protocols with confidence.
Turnkey Referral. No Integration Required.
No EHR integration. No prescription workflow. Refer patients through a streamlined portal. Signos handles fulfillment, onboarding, and AI coaching.
The Solution
What Signos Gives Your Practice
Signos is the first FDA-cleared, over-the-counter continuous glucose monitoring system purpose-built for weight and metabolic management. When practitioners refer patients to Signos, patients receive something no dietary protocol or supplement regimen can provide: a real-time view of how their own body responds to every choice they make.
Paired with Stelo by Dexcom and the Signos AI platform, patients see the metabolic consequences of their choices in real time:
For patients with PCOS, perimenopause, prediabetes, insulin resistance, or post-GLP-1 weight maintenance needs, Signos turns invisible metabolic dysfunction into legible, actionable data.
The App Experience
What Your Patients See Every Day
Large-format, intuitive screens patients actually use — no learning curve, no clinical jargon. Scroll to explore.
Patient Populations
Built for the Patients You Are Already Treating
Signos is clinically relevant across the patient populations that define functional medicine and integrative health practice:
Women with PCOS
1 in 10 women live with PCOS, closely tied to insulin resistance. Signos shows patients in real time how food, stress, and lifestyle choices affect glucose.
Perimenopause & Menopause
Hormonal shifts alter how the body processes glucose, driving weight gain, brain fog, and disrupted sleep. Signos adapts guidance as hormonal needs evolve.
Prediabetes & Insulin Resistance
88% of Americans who are metabolically unhealthy represent the highest-leverage opportunity. Signos identifies glucose instability before it becomes disease.
Post-GLP-1 Graduation
50–80% of patients regain weight after stopping GLP-1s. Signos provides metabolic literacy and real-time feedback that sustains results after medication ends.
Weight Management
Signos provides personalized, body-specific feedback that generic dietary guidance cannot. Insights calibrated to each patient's unique metabolic response.
Metabolic Optimization
For performance or longevity-focused patients, Signos delivers real-time data on how their body responds to food, training, sleep, and stress.
How It Works For Patients
From Sensor to Insight
Real-time data. Real behavior change.
Patients apply a small, discreet Stelo by Dexcom CGM sensor to their upper arm. No fingersticks. No prescription required. The sensor continuously monitors glucose levels across every hour of the day, including meals, sleep, workouts, and everything in between.
Signos AI analyzes hundreds of millions of data points to build each patient's unique metabolic profile. The app surfaces in real time how every food choice, activity, night of sleep, and stress event affects their glucose. Not generic population norms: their body's actual response.
Personalized, in-the-moment guidance helps patients make the small changes that compound. When a food spikes their glucose, the app shows them and suggests what to do differently next time. Habit change backed by biology, not willpower.
Patients log progress toward their personal health goals. Practitioners gain visibility into how their protocols are performing in the real world, between visits rather than only at the appointment.
Partner Program
The Signos Health Partner Program
The Signos health partner program gives functional medicine practitioners a structured, low-friction way to extend metabolic support to their patients, with visibility into outcomes and resources to support clinical conversations.
What's Included
What Is Included in the Partner Program
- Dedicated partner portal for patient referrals and outcome tracking
- Population-level dashboard with real-time engagement and metabolic outcome data
- Clinical education resources: patient-facing one-pagers for PCOS, menopause, prediabetes, and post-GLP-1 support
- Co-branded patient onboarding materials
- Signos team support for practice onboarding. Live in weeks, not quarters.
- HSA/FSA eligible, reducing out-of-pocket cost for your patients
- No EHR integration or prescription workflow required
For Health Partners
Bring Signos to Your Patients
Elevate your functional medicine, longevity, or coaching protocols with real-time glucose data. No implementation fees and free access to the clinical portal. Start in seconds.
Tell us a little more about your practice.
Already a Signos provider? Log in to your admin portal
We respect your privacy and protect your data. Review our Privacy Policy.
Get Started
Give Your Patients the Data to Follow Your Protocols.
Your protocols work. Signos makes sure your patients can see that in real time and stay engaged long enough to prove it.
Don't miss out!
Sign up to be the first to know about special offers and exciting Signos news.
Copyright © 2026 Signos Inc.
Signos indications: The Signos Glucose Monitoring System is an over-the-counter (OTC) mobile device application that receives data from an integrated Continuous Glucose Monitor (iCGM) sensor and is intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Signos Glucose Monitoring System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Signos Glucose Monitoring System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursions. This information may be useful in helping users to maintain a healthy weight.
The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
See user guide for important warnings and precautions.
STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.
STELO INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
OPENLOOP CLINICAL AND PHARMACEUTICAL SERVICES:
Signos is a technology platform and wellness program provider. With the exception of registered dieticians, Signos does not employ licensed health care professionals to practice medicine, does not diagnose, treat, cure, or prevent any disease or medical condition, and does not provide medical advice. You should always consult your own health care professional for diagnosis, treatment, and care regarding any medical condition or health concern. Clinical services accessible through the Signos platform are provided solely by OpenLoop Health and other independent networks of U.S.-licensed clinicians, who exercise their own independent medical judgment to determine eligibility for GLP‑1 treatment based on medical history and assessment responses. These independent providers retain full discretion to prescribe or decline compounded GLP‑1 medications. Signos does not direct, control, or influence any clinical decision made by these providers, and no provider-patient relationship is created between you and Signos.
Compounded medications that may be made available in connection with the Signos program are produced in FDA-registered facilities, but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Signos does not manufacture, compound, dispense, or distribute any medications. Signos partners with certified U.S. pharmacies to help facilitate access to these medications, but Signos makes no representations or warranties regarding the safety, efficacy, suitability, or quality of any compounded medication. Product appearance may differ from website images.
Medication costs are included in the Signos program; however, inclusion of medication costs does not constitute the practice of medicine or pharmacy by Signos. Results may vary and depend on individual adherence, independent provider guidance, and lifestyle changes. Unless otherwise noted, results referenced reflect individual Signos patient experiences rather than public clinical studies, and no particular outcome is guaranteed.
Nothing on this website or within the Signos platform should be construed as medical advice, a medical diagnosis, or a recommendation for any specific treatment. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.